Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
53.94
-0.27 (-0.50%)
Official Closing Price
Updated: 7:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
85
86
Next >
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
Today 14:13 EST
As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...
Via
MarketMinute
Topics
Intellectual Property
2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky
December 31, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the...
Via
StockStory
Topics
Stocks
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
December 31, 2025
As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...
Via
MarketMinute
Topics
Economy
Intellectual Property
Law Enforcement
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
2 Dividend Stocks to Scoop Up Without Hesitation Right Now
↗
December 31, 2025
These stocks can be great sources of portfolio growth in the years ahead.
Via
The Motley Fool
Topics
Bankruptcy
Initial Public Offering
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026?
↗
December 30, 2025
The stock has been on the rebound for several months, but can it keep the momentum going?
Via
The Motley Fool
Topics
Intellectual Property
The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year
December 30, 2025
As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever
↗
December 30, 2025
Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.
Via
The Motley Fool
Topics
Economy
Intellectual Property
3 Drug Stocks to Buy at a Discount
↗
December 27, 2025
The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.
Via
The Motley Fool
Topics
Intellectual Property
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever
↗
December 24, 2025
If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.
Via
The Motley Fool
Topics
Intellectual Property
Bristol Myers Squibb Co (NYSE:BMY) Presents a Classic Value Investing Case Amid Transition
↗
December 24, 2025
Bristol Myers Squibb (BMY) presents a classic value investing case, trading at a significant discount with strong profitability and a high dividend yield, despite near-term patent challenges.
Via
Chartmill
Topics
Intellectual Property
Dividend Stocks Are the Gift that Will Keep On Giving You More Income in 2026
↗
December 24, 2025
These dividend investments can provide you with a growing income stream in 2026.
Via
The Motley Fool
Topics
Economy
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk
↗
December 23, 2025
Via
Stocktwits
Topics
Government
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
December 23, 2025
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...
Via
MarketMinute
Topics
Intellectual Property
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
December 23, 2025
After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The...
Via
MarketMinute
Topics
Economy
Should Retirees Pull Their Money Out of the Stock Market in 2026?
↗
December 21, 2025
Even if you think the market will slump, selling your holdings isn't an ideal strategy.
Via
The Motley Fool
Topics
ETFs
Economy
Retirement
Bristol-Myers Squibb Co (NYSE:BMY) Offers a High-Quality Dividend Profile for Income Investors
↗
December 20, 2025
Bristol-Myers Squibb (BMY) offers a high 4.92% dividend yield with a strong growth history, backed by solid earnings and a satisfactory financial condition for income investors.
Via
Chartmill
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
December 19, 2025
From
Bristol Myers Squibb
Via
Business Wire
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants
↗
December 19, 2025
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.
Via
Stocktwits
Topics
Government
World Trade
This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026
↗
December 19, 2025
This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Economy
Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
December 18, 2025
From
Bristol Myers Squibb
Via
Business Wire
These 2 Healthcare Stocks Just Declared Dividend Raises
↗
December 17, 2025
The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.
Via
The Motley Fool
Topics
Intellectual Property
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks
↗
December 17, 2025
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.
Via
Stocktwits
Topics
Government
World Trade
Why Bristol-Myers Squibb (BMY) Stock Is Up Today
December 15, 2025
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 3.7% in the afternoon session after BofA Securities upgraded the company's stock from "Neutral" to "Buy" and increased its...
Via
StockStory
Stay informed with the top movers within the S&P500 index on Monday.
↗
December 15, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Via
Chartmill
Bristol Myers Squibb (BMS): Navigating the Patent Cliff with a Renewed Pipeline and Strategic Acquisitions
December 15, 2025
Date: December 15, 2025 1. Introduction Bristol Myers Squibb (BMS) (NYSE: BMY) is a global biopharmaceutical powerhouse focused on discovering, developing, manufacturing, and distributing innovative...
Via
PredictStreet
Topics
Intellectual Property
Lawsuit
Supply Chain
Top S&P500 movers in Monday's pre-market session
↗
December 15, 2025
The US market session of Monday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Via
Chartmill
2 Dividend Stocks to Double Up on Right Now
↗
December 14, 2025
These dividend growth machines could have considerable upside for long-term investors.
Via
The Motley Fool
Topics
Economy
Intellectual Property
The Smartest Dividend Stocks to Buy With $1,000 Right Now
↗
December 13, 2025
Here are three stocks offering attractive yields of up to 4.9%, each backed by strong businesses.
Via
The Motley Fool
Topics
Economy
Intellectual Property
Which S&P500 stocks are moving on Friday?
↗
December 12, 2025
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
85
86
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.